Progression and Metastasis of Oral Tongue Cancer

点击翻译按钮获取中文摘要

DESCRIPTION (provided by applicant): TP53 is the most commonly somatically mutated gene in all cancers, and is altered in as many as 85% of squamous cell carcinoma of the oral tongue (SCCOT) cases. While some TP53 mutations lead to a loss of wild-type p53 function, many TP53 mutations have been identified to confer gain of functions (GOF) that promote invasion, metastasis, genomic instability, and cancer cell proliferation. However, the determination of whether a specific mutation will lead to GOF, and the mechanisms involved in mutant p53 GOF activity remain elusive. Our long-term goal is to understand the role of TP53 mutations in promoting aggressiveness of SCCOT, and based on this information, to design and develop effective and precise cancer therapies for SCCOT patients. The objective of this proposal is to understand the impact of different TP53 mutations on the clinical outcomes of SCCOT patients, and to further investigate the mechanisms involved in mutant p53 GOF activity that promote tumor progression and metastasis. Our central hypothesis is that high-risk p53 mutations identified by our newly-developed EAp53 scoring system are associated with mutant p53 GOF activity that contributes to disease progression, metastasis and adverse clinical outcomes, and that mutant p53s achieve gain oncogenic function through positive regulation of the oncogenic transcription factor, FoxM1's expression and stimulation of focal adhesion kinase (FAK) through inhibition of AMPK-mediated signaling in both transcription-dependent and -independent manners. This hypothesis has been formulated on the basis of our recent exciting preliminary data. The rationale for the proposed study is that successful completion of proposed studies will establish clinical significance of EAp53 stratification in predicting clinic outcomes or SCCOT patients, and will provide mechanistic insights into GOF of p53 mutations. Guided by strong preliminary data, this hypothesis will be tested by pursuing three specific aims: 1) Aim 1: Demonstrate the ability of EAp53 to identify p53 mutations associated with adverse clinical outcomes for HNSCC patients, and correlate high-risk p53 mutations with both in vitro and in vivo mutant p53 gain-of-function activity; 2) Aim 2: Demonstrate that high-risk mutant p53 GOF activity inhibits AMPK signaling leading to invasive tumor cell growth and metastasis through transcription-dependent and transcription-independent mechanisms, and 3) Aim 3: Demonstrate that the TP53 codon 72 polymorphism modulates the GOF activity of mutant p53-mediated AMPK inhibition and promotes tumor invasive cell growth and metastasis. Our proposed study is innovative given that the proposed mechanisms and the approaches for studying GOF mutp53 have not been reported before. Our proposed study is also significant since it not only enhances our understanding of the role of mutant p53 in mediating SCCOT disease progression, but also enables us to better prognosticate and treat HNSCC patients at high risk for disease progression and recurrence based on TP53 mutational status.